Safety and Efficacy Study of Interferon to Treat Patients Hospitalized for Influenza

• Status: Unknown status
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

A Pilot Study to Evaluate the Safety and Efficacy of interferon-Alfacon1 (INFERGEN) in the treatment of patients hospitalized with Influenza-like illness caused by a novel swine origin Influenza virus and other circulating Influenza Viruses.

The use of Interferon-alfacon1 as a co-treatment along with the standard of care antiviral is hypothesized to be safe. Clinical improvement of patients is hypothesized to be quicker.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Health Network, Toronto
• Treatments: Interferon alfacon-1; Interferons

Criteria

Inclusion Criteria:

• Able to provide informed consent

• Aged >=18 and < 70

• Hospitalized

• suspect, probable, confirmed influenza A

• symptom onset <8 days

• able to attend all scheduled visits

Exclusion Criteria:

• known hypersensitivity to interferon preparation

• pregnancy

• chronic liver disease

• moderate to severe congestive heart failure, grade III or IV left ventricular function

• previous history of serious psychiatric illness

• history of severe or active autoimmune disease